Cargando…
Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549142/ https://www.ncbi.nlm.nih.gov/pubmed/26305791 http://dx.doi.org/10.1371/journal.pone.0136826 |
| _version_ | 1782387279195537408 |
|---|---|
| author | Li, Qian Liu, Mei Ma, Fei Luo, Yang Cai, Ruigang Wang, Liming Xu, Ningzhi Xu, Binghe |
| author_facet | Li, Qian Liu, Mei Ma, Fei Luo, Yang Cai, Ruigang Wang, Liming Xu, Ningzhi Xu, Binghe |
| author_sort | Li, Qian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4549142 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-45491422015-09-01 Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel Li, Qian Liu, Mei Ma, Fei Luo, Yang Cai, Ruigang Wang, Liming Xu, Ningzhi Xu, Binghe PLoS One Correction Public Library of Science 2015-08-25 /pmc/articles/PMC4549142/ /pubmed/26305791 http://dx.doi.org/10.1371/journal.pone.0136826 Text en © 2015 Li et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
| spellingShingle | Correction Li, Qian Liu, Mei Ma, Fei Luo, Yang Cai, Ruigang Wang, Liming Xu, Ningzhi Xu, Binghe Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel |
| title | Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel |
| title_full | Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel |
| title_fullStr | Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel |
| title_full_unstemmed | Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel |
| title_short | Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel |
| title_sort | correction: circulating mir-19a and mir-205 in serum may predict the sensitivity of luminal a subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549142/ https://www.ncbi.nlm.nih.gov/pubmed/26305791 http://dx.doi.org/10.1371/journal.pone.0136826 |
| work_keys_str_mv | AT liqian correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT liumei correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT mafei correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT luoyang correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT cairuigang correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT wangliming correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT xuningzhi correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT xubinghe correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel |